Intralesional therapy with anti-CD20 monoclonal antibody rituximab: Local and systemic efficacy in primary cutaneous B-cell lymphoma

British Journal of Dermatology

Volumn 152, Issue 3, 2005, Pages 541-544

  Roguedas, A M ^a   Watier, H ^a   Paintaud, G ^a   De Muret, A ^a   Vaillant, L ^a   Machet, L ^a  

^a UNIVERSITÉ DE TOURS   (France)

Author keywords

CD20; Follicular centre cell lymphoma; Intralesional therapy; MabThera ; Primary cutaneous B cell lymphoma; Rituximab

Indexed keywords

CD20 ANTIBODY; CYCLOPHOSPHAMIDE; PREDNISOLONE; RITUXIMAB; VINDESINE;

ADULT; ARTICLE; B CELL LYMPHOMA; CASE REPORT; DRUG DIFFUSION; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; INJECTION PAIN; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; TUMOR REGRESSION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; HUMANS; INJECTIONS, INTRALESIONAL; LYMPHOMA, B-CELL; MALE; SKIN NEOPLASMS;

EID: 17444427686     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06433.x     Document Type: Article

References (22)

1. Fink-Puches R, Zenahlik P, Back B et al. Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients. Blood 2002; 99:800-5.
2. Rijlaarsdam JU, Toonstra J, Meijer OW et al. Treatment of primary cutaneous B-cell lymphomas of follicle center cell origin: a clinical follow-up study of 55 patients treated with radiotherapy or polychemotherapy. J Clin Oncol 1996; 14:549-55.
3. Bekkenk MW, Vermeer MH, Geerts ML et al. Treatment of multifocal primary cutaneous B-cell lymphoma: a clinical follow-up study of 29 patients. J Clin Oncol 1999; 17:2471-8.
4. Pandolfino TL, Siegel RS, Kuzel TM et al. Primary cutaneous B-cell lymphoma: review and current concepts. J Clin Oncol 2000; 18:2152-68.
5. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-33.
6. Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97:101-6.
7. Sabroe RA, Child FJ, Woolford AJ et al. Rituximab in cutaneous B-cell lymphoma: a report of two cases. Br J Dermatol 2000; 143:157-61.
8. Heinzerling LM, Urbanek M, Funk JO et al. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer 2000; 89:1835-44.
9. Aboulafia DM. Primary cutaneous large B-cell lymphoma of the legs: a distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab). Am J Clin Oncol 2001; 24:237-40.
10. Gellrich S, Muche JM, Pelzer K et al. Der anti-CD20-Antikörper bei primär kutanen B-zell-Lymphomen. Erste Erfahrungen in der dermatologischen Anwendung. Hautarzt 2001; 52:205-10.
11. Viguier M, Bachelez H, Brice P et al. Lymphomes cutanés B traités par rituximab: deux cas. Ann Dermatol Venereol 2002; 129:1152-5.
12. Fierro MT, Savoia P, Quaglino P et al. Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases. J Am Acad Dermatol 2003; 49:281-7.
13. Heinzerling LM, Dummer R, Kempf W et al. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma. Arch Dermatol 2000; 136:374-8.
14. Paul T, Radny P, Krober SM et al. Intralesional rituximab for cutaneous B-cell lymphoma. Br J Dermatol 2001; 144:1239-43.
15. Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002; 99:754-78.
16. Yang H, Rosove MH, Figlin RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Hematol 1999; 62:247-50.
17. Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low grade non-Hodgkin's lymphoma. Blood 1997; 90:2188-95.
18. Berinstein NL, Grillo-Lopez AJ, White CA. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9:995-1001.
19. Tobinai K, Kobayashi Y, Narabayashi M et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol 1998; 9:527-34.
20. Dall'Ozzo S, Tartas S, Paintaud G et al. Rituximab-mediated ADCC by NK cells: influence of FCGR3A polymorphism on the concentration-efect relationship. Cancer Res 2004; 64:4664-9.
21. Selenko N, Maidic O, Draxier S et al. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia 2001; 15:1619-26.
22. Dhodapkar KM, Krasovsky J, Williamson B et al. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 2002; 195:125-33.